1. Home
  2. MREO vs TLPH Comparison

MREO vs TLPH Comparison

Compare MREO & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

SELL

Current Price

$0.30

Market Cap

50.3M

Sector

Health Care

ML Signal

SELL

Logo Talphera Inc.

TLPH

Talphera Inc.

HOLD

Current Price

$0.86

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MREO
TLPH
Founded
2015
2005
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.3M
54.5M
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
MREO
TLPH
Price
$0.30
$0.86
Analyst Decision
Buy
Strong Buy
Analyst Count
8
4
Target Price
$1.96
★ $3.13
AVG Volume (30 Days)
★ 632.5K
136.1K
Earning Date
11-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 16.67
N/A
EPS
★ N/A
N/A
Revenue
$500,000.00
★ $2,151,000.00
Revenue This Year
$59.51
N/A
Revenue Next Year
$2,326.81
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.20
$0.69
52 Week High
$2.37
$1.57

Technical Indicators

Market Signals
Indicator
MREO
TLPH
Relative Strength Index (RSI) 50.90 27.26
Support Level $0.27 $0.74
Resistance Level $0.35 $0.89
Average True Range (ATR) 0.02 0.07
MACD 0.00 -0.01
Stochastic Oscillator 62.55 22.73

Price Performance

Historical Comparison
MREO
TLPH

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About TLPH Talphera Inc.

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Share on Social Networks: